Pressure BioSciences is a life science, medical device company that developments and commercializes pressure cycling technology (PCT) which uses instrumentation that cycles pressure between ambient and ultra-high levels at controlled temperatures to control the interactions of bio-molecules.
In the article from contributor Vineet Dutta, it was revealed that biotech services giant Thermo Fisher's (NYSE:TMO) unit Cole-Parmer recently agreed to carry Pressure BioSciences' PBI Shredder SG3 System.
"This could end up being a significant opportunity for PBIO because Cole-Parmer happens to be one of the world's largest and most recognized distributors of lab equipment and supplies," Dutta wrote in the online article.
Cole-Parmer's catalogues land in the hands of "most if not all" of the people who run laboratories all over the world, Dutta wrote.
"With Thermo Fisher's backing, Cole-Parmer's many decades of experience and hundreds of thousands of customers, and a new distribution platform, this deal has the potential of developing into a long and profitable relationship for PBIO as the relationship develops and Cole-Parmer adds more of PBIO's products to its catalogue."
Dutta wrote that the benefit of the PBI Shredder SG3 System comes in the form of achieving improved safety and sample integrity, better versatility, and longer DNA.
PBIO's instrument is ideal for the extraction of DNA, RNA, protein, mitochondria, and small molecules - a routine process done in thousands of labs, the Seeking Alpha contributor wrote.
The device offers a unique a closed system in which to safely prepare samples compared to its competitors that are generally open systems. The PBI System is also portable for easy and efficient field collection.
PBIO's Shredder SG3 System is already available for purchase on Cole-Parmer's website.
PBIO competes in the estimated $6 billion life sciences sample preparation market.
"As a small, rapidly growing company, it seems to make a lot of sense for PBIO to team up with one of the biggest and best in its industry," Dutta wrote on Seeking Alpha.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.